NCT03224104 2025-11-26
STEAM
European Organisation for Research and Treatment of Cancer - EORTC
Phase 1 Completed
Clinical Trials
10 trialsNCT02975882 2025-01-14
Nanoparticle Albumin-Bound Rapamycin, Temozolomide, and Irinotecan Hydrochloride in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors
Children's Oncology Group
Phase 1 Completed
NCT03323034 2024-10-22
Pevonedistat, Irinotecan, and Temozolomide in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphoma
Children's Oncology Group
Phase 1 Completed
NCT00138216 2023-10-02
Temozolomide, Vincristine, and Irinotecan in Treating Young Patients With Refractory Solid Tumors
Children's Oncology Group
Phase 1 Completed
NCT00387400 2023-08-04
Temozolomide + Everolimus in Newly Diagnosed, Recurrent, or Progressive Malignant Glioblastoma Multiforme
Canadian Cancer Trials Group
Phase 1 Completed
NCT04091503 2023-04-25
Evaluate the Safety and Effectiveness of Intranasal Administration of Temozolomide in Patients With Glioblastoma
Center Trials & Treatment Europe
Phase 1 Completed
NCT00083096 2015-02-10
Lonafarnib and Temozolomide in Treating Patients With Recurrent Primary Supratentorial Gliomas
European Organisation for Research and Treatment of Cancer - EORTC
Phase 1 Unknown
NCT00516607 2015-02-10
Enzastaurin and Temozolomide in Treating Patients With Primary Gliomas
European Organisation for Research and Treatment of Cancer - EORTC
Phase 1 Unknown
NCT00083070 2014-02-20
Temozolomide in Treating Young Patients With Refractory or Recurrent Leukemia
Children's Oncology Group
Phase 1 Completed
NCT00006024 2014-02-13
Temozolomide Plus Lomustine Followed by Radiation Therapy in Treating Patients With High-Grade Malignant Glioma
Children's Oncology Group
Phase 1 Completed